We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
ABIOMED (ABMD) Banks on Impella Platform, Competition Rife
Read MoreHide Full Article
On Mar 12, we issued an updated research report on ABIOMED, Inc. , a leading medical product developer. The stock carries a Zacks Rank #3 (Hold). The company's robust demand for the Impella product line has been the key growth catalyst. However, stiff competition adds to the woes.
Impella, ABIOMED’s flagship product line, has continued to be growth driver. Impella is the world's smallest heart pump. It is a support system of percutaneous, catheter-based devices offering hemodynamic support to the heart. The platform reflected stellar performance in the third quarter.
The market is upbeat about ABIOMED’s flagship Impella 2.5 and Impella CP heart-pumps receiving Pre-Market Approval (PMA) from the FDA for expanded use. To note, the Impella support has already been integrated in hospitals throughout Germany and Japan.
Also, ABIOMED recently announced expanded FDA Pre-Market Approval (PMA) for its flagship Impella 2.5, Impella CP, Impella 5.0 and Impella LD heart pumps.
In the past year, ABIOMED has returned 144.5% outperforming the S&P 500’s 18% gain over the same time frame. The current level is also better than the industry's growth of 27.6%.
Competition among treatment providers for heart-related diseases is intense and is subject to rapid technological change, and evolving industry requirements and standards. ABIOMED’s products compete with a temporary cardiac assist device from Throated, which was acquired by St. Jude. The company also faces stiff competition from organizations developing permanent heart assist products.
Of the other major headwinds, ABIOMED is likely to face increasing pricing pressure due to growing competitionin its key markets. Also, stretched valuation and currency fluctuations add to the woes.
Key Picks
A few better-ranked stocks in the broader medical sector are PerkinElmer , Bio-Rad Laboratories (BIO - Free Report) and athenahealth, Inc. .
PerkinElmer has a long-term expected earnings growth rate of 12.3%. The stock carries a Zacks Rank #2 (Buy).
athenahealth is a Zacks #1 Ranked player. The company has a long-term expected earnings growth rate of 21.5%.
Zacks Top 10 Stocks for 2018
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2018?
Last year's 2017 Zacks Top 10 Stocks portfolio produced double-digit winners, including FMC Corp. and VMware which racked up stellar gains of +67.9% and +61%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.
Image: Bigstock
ABIOMED (ABMD) Banks on Impella Platform, Competition Rife
On Mar 12, we issued an updated research report on ABIOMED, Inc. , a leading medical product developer. The stock carries a Zacks Rank #3 (Hold). The company's robust demand for the Impella product line has been the key growth catalyst. However, stiff competition adds to the woes.
Impella, ABIOMED’s flagship product line, has continued to be growth driver. Impella is the world's smallest heart pump. It is a support system of percutaneous, catheter-based devices offering hemodynamic support to the heart. The platform reflected stellar performance in the third quarter.
The market is upbeat about ABIOMED’s flagship Impella 2.5 and Impella CP heart-pumps receiving Pre-Market Approval (PMA) from the FDA for expanded use. To note, the Impella support has already been integrated in hospitals throughout Germany and Japan.
Also, ABIOMED recently announced expanded FDA Pre-Market Approval (PMA) for its flagship Impella 2.5, Impella CP, Impella 5.0 and Impella LD heart pumps.
In the past year, ABIOMED has returned 144.5% outperforming the S&P 500’s 18% gain over the same time frame. The current level is also better than the industry's growth of 27.6%.
Competition among treatment providers for heart-related diseases is intense and is subject to rapid technological change, and evolving industry requirements and standards. ABIOMED’s products compete with a temporary cardiac assist device from Throated, which was acquired by St. Jude. The company also faces stiff competition from organizations developing permanent heart assist products.
Of the other major headwinds, ABIOMED is likely to face increasing pricing pressure due to growing competitionin its key markets. Also, stretched valuation and currency fluctuations add to the woes.
Key Picks
A few better-ranked stocks in the broader medical sector are PerkinElmer , Bio-Rad Laboratories (BIO - Free Report) and athenahealth, Inc. .
PerkinElmer has a long-term expected earnings growth rate of 12.3%. The stock carries a Zacks Rank #2 (Buy).
Bio-Rad Laboratories sports a Zacks Rank of 1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here. The company has a long-term expected earnings growth rate of 20%.
athenahealth is a Zacks #1 Ranked player. The company has a long-term expected earnings growth rate of 21.5%.
Zacks Top 10 Stocks for 2018
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2018?
Last year's 2017 Zacks Top 10 Stocks portfolio produced double-digit winners, including FMC Corp. and VMware which racked up stellar gains of +67.9% and +61%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.
Access Zacks Top 10 Stocks for 2018 today >>